10-Q · May 13, 2026
Enanta Pharmaceuticals reported Q2 2026 revenues of $17.2 million, reflecting a 15.4% increase from $14.9 million in Q2 2025. The net loss narrowed to $13.1 million compared to $22.6 million in the prior-year quarter,…
Earnings analysis · 10-Q
ENTA earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Enanta reported Q3 revenue of $14.359 million and diluted EPS of $(0.67), missing consensus revenue of $17.08664 million and EPS of $(0.48). Revenue fell from $17 million in Q2 2026 and $18 million in Q3 2025, while EPS…
Read full summary
Enanta reported Q3 revenue of $14.359 million and diluted EPS of $(0.67), missing consensus revenue of $17.08664 million and EPS of $(0.48). Revenue fell from $17 million in Q2 2026 and $18 million in Q3 2025, while EPS deteriorated sequentially from $(0.45) but improved from $(0.85) a year earlier. The provided filing text contains no updated quantitative guidance, balance-sheet, cash-flow, or segment disclosures.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.67
What stood out
-
Revenue Declined Sequentially and Year Over Year
Q3 revenue was $14.359 million, down approximately 15.4% from $17 million in Q2 2026 and 20.2% from $18 million in Q3 2025.
-
EPS Missed Consensus
Diluted EPS was $(0.67), compared with $(0.45) in Q2 2026 and $(0.85) in Q3 2025, representing a sequential deterioration but improvement versus the prior-year quarter.
-
Quarter Missed Revenue and EPS Estimates
Reported EPS of $(0.67) was $0.19 below the $0.48 consensus estimate, while revenue of $14.359 million was approximately $3.727 million below the $17.08664 million estimate.
-
Controls Remained Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes in internal control that materially affected, or were reasonably likely to materially affect, controls during the three months ended June 30, 2026.
What to watch
-
No New Risk-Factor Changes Disclosed
The company stated that there were no material changes to its previously disclosed risk factors during the three months ended June 30, 2026; therefore, the filing does not identify a newly elevated risk relative to the 2025 Form 10-K.
Management's outlook
The provided 10-Q text does not include quantitative revenue or EPS guidance. Prior company commentary indicated sufficient liquidity through fiscal 2029, but no updated outlook is provided in the extracted filing text.
Earlier filings 4
10-Q · February 11, 2026
Enanta reported Q1 revenue of $18,615 (in thousands) and a narrower net loss of $11,938 (net loss per share $0.42) versus $22,290 a year ago (EPS -$1.05). Revenue and operating performance improved versus the prior-year…
10-Q · May 14, 2025
Enanta reported Q3 (three months ended March 31, 2025) royalty revenue of $14,926,000 (down from $17,054,000 a year earlier) and GAAP diluted loss per share of $(1.06), which improved from $(1.47) in the prior-year…
10-K · November 22, 2023
Enanta remains a royalty‑funded virology-focused discovery and development company with a cash‑rich balance sheet following a $200.0 million royalty sale to OMERS in April 2023. The company reported fiscal 2023 revenue…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.